New transplant prep shows promise for tough leukemia cases
NCT ID NCT00534430
First seen Jun 03, 2026 · Last updated Jun 22, 2026 · Updated 5 times
Summary
This study tested a combination of chemotherapy (busulfan and etoposide) and total-body radiation given before a donor stem cell or bone marrow transplant. The goal was to see how well this regimen works and what side effects it causes in 30 patients with advanced leukemia or myelodysplastic syndromes. Researchers measured survival and relapse rates over five years after transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
busulfan, etoposide, total-body irradiation, cyclosporine, mycophenolate mofetil
What this could lead to
If successful, this regimen could improve long-term survival and reduce relapse for patients with advanced blood cancers who need a transplant.
What could go wrong
This is a small, completed phase 2 trial with only 30 patients, so results may not apply broadly. The intensive regimen carries risks like infection, organ damage, and graft-versus-host disease.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.